Loading
A phase 3 trial of Triptorelin in Prostate cancer, run by Ipsen, completed.
Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer is a phase 3 interventional study registered as NCT01020448 by Ipsen, with 339 participants recorded, started 2009-11 and reaching its primary completion in 2011-11. Interventions recorded: Triptorelin (Decapeptyl®). Conditions recorded: Prostate Cancer.
Linked to the drug Triptorelin because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Triptorelin, Prostate cancer and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Triptorelin and the tag pipeline.
Shares Ipsen and the tag pipeline.
Shares Triptorelin and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/